Tomoko Haruma1, Keiichiro Nakamura2, Takeshi Nishida1, Chikako Ogawa1, Tomoyuki Kusumoto1, Noriko Seki1, Yuji Hiramatsu1. 1. Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. 2. Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan k-nakamu@cc.okayama-u.ac.jp.
Abstract
BACKGROUND/AIM: Inflammation and tumor immunology are important in the prognosis of various cancers. We herein investigated whether pre-treatment neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and serum cancer antigen 125 (CA125) predict recurrence and survival in patients with endometrial cancer (EC). PATIENTS AND METHODS: We collected complete blood counts and clinicopathological data from medical records of 320 patients with EC; their pre-treatment NLR, PLR and CA125 were analyzed for correlations with recurrence and survival, retrospectively. RESULTS: Disease-free survival (DFS) and overall survival (OS) rates of patients with high NLR and CA125 were significantly shorter than those for patients with low NLR and CA125 (DFS: p=0.002 and p<0.001; OS: p<0.001 and p<0.001, respectively). Furthermore, NLR was also an independent predictive factor for mortality in multivariate analysis (hazard ratio (HR)=3.318; 95% confidence interval (CI)=1.154-9.538; p=0.026). CONCLUSION: Pre-treatment NLR is a predictor of poor prognosis in EC. Copyright
BACKGROUND/AIM: Inflammation and tumor immunology are important in the prognosis of various cancers. We herein investigated whether pre-treatment neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and serum cancer antigen 125 (CA125) predict recurrence and survival in patients with endometrial cancer (EC). PATIENTS AND METHODS: We collected complete blood counts and clinicopathological data from medical records of 320 patients with EC; their pre-treatment NLR, PLR and CA125 were analyzed for correlations with recurrence and survival, retrospectively. RESULTS: Disease-free survival (DFS) and overall survival (OS) rates of patients with high NLR and CA125 were significantly shorter than those for patients with low NLR and CA125 (DFS: p=0.002 and p<0.001; OS: p<0.001 and p<0.001, respectively). Furthermore, NLR was also an independent predictive factor for mortality in multivariate analysis (hazard ratio (HR)=3.318; 95% confidence interval (CI)=1.154-9.538; p=0.026). CONCLUSION: Pre-treatment NLR is a predictor of poor prognosis in EC. Copyright
Authors: M Cummings; L Merone; C Keeble; L Burland; M Grzelinski; K Sutton; N Begum; A Thacoor; B Green; J Sarveswaran; R Hutson; N M Orsi Journal: Br J Cancer Date: 2015-06-16 Impact factor: 7.640
Authors: Wan Kyu Eo; Sanghoon Kwon; Suk Bong Koh; Min Jeong Kim; Yong Il Ji; Ji Young Lee; Dong Soo Suh; Ki Hyung Kim; Heung Yeol Kim Journal: J Cancer Date: 2016-02-20 Impact factor: 4.207
Authors: Katarzyna Holub; Fabio Busato; Sebastien Gouy; Roger Sun; Patricia Pautier; Catherine Genestie; Philippe Morice; Alexandra Leary; Eric Deutsch; Christine Haie-Meder; Albert Biete; Cyrus Chargari Journal: J Clin Med Date: 2020-05-12 Impact factor: 4.241
Authors: Michal Mleko; Kazimierz Pitynski; Elzbieta Pluta; Aleksandra Czerw; Katarzyna Sygit; Beata Karakiewicz; Tomasz Banas Journal: Cancer Manag Res Date: 2021-07-09 Impact factor: 3.989